Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 13.8% – Time to Buy?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shot up 13.8% on Thursday . The company traded as high as $27.06 and last traded at $26.48. 571,797 shares changed hands during trading, a decline of 50% from the average session volume of 1,146,256 shares. The stock had previously closed at $23.27.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZBIO. HC Wainwright reiterated a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a report on Tuesday. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Wall Street Zen lowered shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Wedbush reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Monday, December 22nd. Finally, Morgan Stanley cut shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $37.00 to $19.00 in a research report on Monday, January 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Stock Performance

The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The stock has a market cap of $1.40 billion, a PE ratio of -3.69 and a beta of -1.50. The business has a 50 day moving average price of $28.06 and a two-hundred day moving average price of $25.51.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Activity at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. bought 57,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was bought at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the acquisition, the chief executive officer owned 423,155 shares in the company, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have bought 157,000 shares of company stock worth $2,662,720 over the last ninety days. Corporate insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBIO. Quarry LP lifted its holdings in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after buying an additional 291 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Zenas BioPharma during the third quarter valued at approximately $30,000. GF Fund Management CO. LTD. purchased a new stake in Zenas BioPharma in the fourth quarter worth $38,000. BNP Paribas Financial Markets boosted its holdings in Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares in the last quarter. Finally, CWM LLC boosted its holdings in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.